Shinpoong Pharmaceutical Co.,Ltd (KRX:019170)
South Korea
· Delayed Price · Currency is KRW 11,830
+50 (0.42%)
Apr 29, 2026, 2:30 PM KST
KRX:019170 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 234,681 | 221,094 | 200,229 | 209,288 | 189,237 | Upgrade
|
| Other Revenue | - | - | - | -0 | - | Upgrade
|
| Revenue | 234,681 | 221,094 | 200,229 | 209,288 | 189,237 | Upgrade
|
| Revenue Growth (YoY) | 6.14% | 10.42% | -4.33% | 10.60% | -4.30% | Upgrade
|
| Cost of Revenue | 132,010 | 139,290 | 119,951 | 131,315 | 111,850 | Upgrade
|
| Gross Profit | 102,671 | 81,804 | 80,277 | 77,973 | 77,388 | Upgrade
|
| Selling, General & Admin | 76,939 | 77,764 | 79,068 | 76,549 | 69,256 | Upgrade
|
| Research & Development | 10,443 | 17,879 | 42,277 | 30,383 | 17,334 | Upgrade
|
| Amortization of Goodwill & Intangibles | 540.74 | 969.42 | 1,182 | 1,358 | 1,496 | Upgrade
|
| Other Operating Expenses | -143.43 | 800.65 | 394.37 | 646.98 | 3,241 | Upgrade
|
| Operating Expenses | 88,416 | 98,833 | 127,670 | 111,992 | 91,694 | Upgrade
|
| Operating Income | 14,255 | -17,029 | -47,392 | -34,019 | -14,306 | Upgrade
|
| Interest Expense | -2,688 | -2,632 | -1,719 | -61.42 | -202.06 | Upgrade
|
| Interest & Investment Income | 767.26 | 704.06 | 1,174 | 1,026 | 1,878 | Upgrade
|
| Earnings From Equity Investments | - | - | -6,514 | -697.09 | 2,620 | Upgrade
|
| Currency Exchange Gain (Loss) | -1,232 | 2,833 | 1,328 | -1,009 | 406.81 | Upgrade
|
| Other Non Operating Income (Expenses) | 167.43 | 279.23 | 653.36 | -182.48 | 314.91 | Upgrade
|
| EBT Excluding Unusual Items | 11,269 | -15,844 | -52,471 | -34,942 | -9,288 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2,820 | 1,215 | -1,011 | 845.62 | 253.64 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.54 | 6.89 | 39.65 | 18.31 | 49.02 | Upgrade
|
| Asset Writedown | - | - | - | -703.23 | - | Upgrade
|
| Pretax Income | 8,452 | -14,622 | -53,442 | -34,782 | -8,986 | Upgrade
|
| Income Tax Expense | 62.48 | 751.41 | 3,831 | 527.29 | 2,540 | Upgrade
|
| Earnings From Continuing Operations | 8,389 | -15,373 | -57,273 | -35,309 | -11,526 | Upgrade
|
| Minority Interest in Earnings | 435.95 | -13.8 | -52.86 | -68.14 | -57.61 | Upgrade
|
| Net Income | 8,825 | -15,387 | -57,325 | -35,377 | -11,584 | Upgrade
|
| Net Income to Common | 8,825 | -15,387 | -57,325 | -35,377 | -11,584 | Upgrade
|
| Shares Outstanding (Basic) | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Change (YoY) | 0.37% | -0.28% | - | - | 1.85% | Upgrade
|
| EPS (Basic) | 172.00 | -301.00 | -1118.28 | -690.12 | -225.97 | Upgrade
|
| EPS (Diluted) | 172.00 | -301.00 | -1118.28 | -690.12 | -225.97 | Upgrade
|
| Free Cash Flow | 13,776 | -20,724 | -39,696 | -31,767 | -75,453 | Upgrade
|
| Free Cash Flow Per Share | 268.50 | -405.39 | -774.37 | -619.69 | -1471.90 | Upgrade
|
| Gross Margin | 43.75% | 37.00% | 40.09% | 37.26% | 40.89% | Upgrade
|
| Operating Margin | 6.07% | -7.70% | -23.67% | -16.25% | -7.56% | Upgrade
|
| Profit Margin | 3.76% | -6.96% | -28.63% | -16.90% | -6.12% | Upgrade
|
| Free Cash Flow Margin | 5.87% | -9.37% | -19.82% | -15.18% | -39.87% | Upgrade
|
| EBITDA | 25,648 | -5,066 | -35,484 | -21,215 | -1,631 | Upgrade
|
| EBITDA Margin | 10.93% | -2.29% | -17.72% | -10.14% | -0.86% | Upgrade
|
| D&A For EBITDA | 11,393 | 11,963 | 11,908 | 12,803 | 12,675 | Upgrade
|
| EBIT | 14,255 | -17,029 | -47,392 | -34,019 | -14,306 | Upgrade
|
| EBIT Margin | 6.07% | -7.70% | -23.67% | -16.25% | -7.56% | Upgrade
|
| Effective Tax Rate | 0.74% | - | - | - | - | Upgrade
|
| Advertising Expenses | 11,855 | 16,981 | 17,979 | 19,126 | 17,097 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.